Trial Profile
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2019
Price :
$35
*
At a glance
- Drugs MT 3724 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Molecular Templates
- 09 Dec 2019 According to Molecular Templates, results presented at American Society of Hematology (ASH) 2019 Annual Meeting.
- 09 Dec 2019 Results published in Molecular Templates Media Release
- 09 Oct 2019 Status changed from recruiting to completed.